Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP): A Phase II, multicenter randomized controlled clinical trial

Carol L. Hodgson, D. James Cooper, Yaseen Arabi, Victoria King, Andrew Bersten, Shailesh Bihari, Kathy Brickell, Andrew Davies, Ciara Fahey, John Fraser, Shay McGuinness, Lynne Murray, Rachael Parke, Eldho Paul, David Tuxen, Shirley Vallance, Meredith Young, Alistair Nichol

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Rationale: Open lung ventilation strategies have been recommended in patients with acute respiratory distress syndrome (ARDS). Objectives: To determine whether a maximal lung recruitment strategy reduces ventilator-free days in patients with ARDS. Methods: A phase II, multicenter randomized controlled trial in adults with moderate to severe ARDS. Patients received maximal lung recruitment, titrated positive end expiratory pressure and further VT limitation, or control "protective" ventilation. Measurements and Main Results: The primary outcome was ventilator-free days at Day 28. Secondary outcomes included mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay. Enrollment halted October 2, 2017, after publication of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a planned 340 patients had been randomized (57% male; mean age, 53.6 yr). At 28 days after randomization, there was no difference between the maximal lung recruitment and control ventilation strategies in ventilator-free days (median, 16 d [interquartile range (IQR), 0-21 d], n = 57, vs. 14.5 d [IQR, 0-21.5 d], n = 56; P = 0.95), mortality (24.6% [n = 14/56] vs. 26.8% [n = 15/56]; P = 0.79), or the rate of barotrauma (5.2% [n = 3/57] vs. 10.7% [n = 6/56]; P = 0.32). However, the intervention group showed reduced use of new hypoxemic adjuvant therapies (i.e., inhaled nitric oxide, extracorporeal membrane oxygenation, prone; median change from baseline 0 [IQR, 0-1] vs. 1 [IQR, 0-1]; P = 0.004) and increased rates of new cardiac arrhythmia (n=17 [29%] vs. n = 7 [13%]; P = 0.03). Conclusions: Compared with control ventilation, maximal lung recruitment did not reduce the duration of ventilation-free days or mortality and was associated with increased cardiovascular adverse events but lower use of hypoxemic adjuvant therapies.

Original languageEnglish
Pages (from-to)1363-1372
Number of pages10
JournalAmerican journal of respiratory and critical care medicine
Volume200
Issue number11
DOIs
Publication statusPublished - 1 Dec 2019
Externally publishedYes

Keywords

  • ARDS
  • Clinical trial
  • Hypoxia
  • ICU
  • Ventilation

Fingerprint Dive into the research topics of 'Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP): A Phase II, multicenter randomized controlled clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Hodgson, C. L., Cooper, D. J., Arabi, Y., King, V., Bersten, A., Bihari, S., Brickell, K., Davies, A., Fahey, C., Fraser, J., McGuinness, S., Murray, L., Parke, R., Paul, E., Tuxen, D., Vallance, S., Young, M., & Nichol, A. (2019). Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP): A Phase II, multicenter randomized controlled clinical trial. American journal of respiratory and critical care medicine, 200(11), 1363-1372. https://doi.org/10.1164/rccm.201901-0109OC